Lv42
660 积分 2024-05-01 加入
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
2个月前
已完结
EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
3个月前
已完结
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
3个月前
已完结
Hallmarks of Cancer: New Dimensions
4个月前
已完结
Catumaxomab: First Approval
4个月前
已关闭
TL1A/DR3 signaling regulates the generation of pathogenic Th9 cells in experimental Crohn's disease
5个月前
已完结
Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy
1年前
已完结
Recognizing, defining, and managing CAR-T hematologic toxicities
1年前
已关闭
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
1年前
已完结
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
1年前
已完结
皖公网安备34019202002308
